Aclaris CSO Joseph Monahan shifts to part-time; base salary reduced to $280,800

Aclaris Therapeutics, Inc.

Monahan will serve as Chief Scientific Officer at 60% of full-time schedule as of July 1, 2023.
Annual base salary reduced to $280,800; annual bonus eligibility pro-rated for part-time service.
Amended employment agreement has initial two-year term with automatic one-year renewals unless 90-day notice given.
Monahan remains in role; prior agreement superseded.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Joseph Monahan

Chief Scientific Officer

ACRS · Aclaris Therapeutics, Inc.

Effective: 2023-07-01
Filed: June 12, 2023, 7:59 PM ET

Dr. Monahan will continue to serve as the Company’s Chief Scientific Officer but will shift to part-time status, pursuant to which he will provide services at 60% of a full-time schedule.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Joseph Monahan changed role as Chief Scientific Officer at Aclaris Therapeutics, Inc..

Action: Shift to part-time status
Role: Chief Scientific Officer

Exact text from the filing

Dr. Monahan will continue to serve as the Company’s Chief Scientific Officer but will shift to part-time status, pursuant to which he will provide services at 60% of a full-time schedule.

View on SEC.gov

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-010987

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.